regulatory
confidence high
sentiment positive
materiality 0.85
Ardelyx announces FDA approval of XPHOZAH (tenapanor) for hyperphosphatemia in dialysis patients
ARDELYX, INC.
- FDA approved XPHOZAH to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy.
- Indicated for patients with inadequate response to phosphate binders or intolerant of any dose.
- XPHOZAH is a single tablet taken twice daily with a first-in-class mechanism blocking phosphate absorption.
- Approval date: October 17, 2023.